Journal · Metabolic
Metabolism Is an Information System: Retatrutide, GHRH vs GHRP, and the Logic of Stacking
The short answer
Metabolism isn’t a calorie equation. It’s a communication network, and peptides carry most of the messages. That changes how a stack should be built: fix the main metabolic signal first, and only then add growth hormone support. Retatrutide sits at one end of that logic. The GHRH and GHRP classes sit at the other.
Questions this article answers
Metabolism runs on messages
Metabolic Precision opens (p. 28) with a single observation: metabolic state isn’t set by calories alone, it’s governed by communication. Energy production, fat storage and release, blood sugar control and hormone output all run on signalling molecules telling tissues what to do.
Peptides are among the most important of those messages. Insulin moves glucose into tissues. GLP-1 coordinates insulin release after meals and reduces appetite. GIP influences insulin and fat tissue. Ghrelin signals hunger. Glucagon releases stored glucose when you’re fasting. As the book puts it on p. 31, metabolism is an information system, and peptides are its primary language.
How a peptide delivers its message
Section 1.1 uses the lock-and-key picture. Receptors on cells respond only to molecules with the right shape, and peptides are often those keys. Binding sets off a chain of events inside the cell that can change gene activity, enzyme activity or energy use.
GLP-1 shows why that matters. In the pancreas it triggers glucose-dependent insulin release. In the brain it reduces appetite. In the gut it slows stomach emptying. One molecule, several targets, each effect meaningful.
The other half of Section 1.1 is the part people forget: peptides act inside feedback loops. Push one pathway and the body adjusts receptor sensitivity or hormone release to compensate. That’s why what the body does in response to a peptide matters as much as the dose that goes in.
Retatrutide: three messages in one molecule
Retatrutide is an investigational weekly injection from Eli Lilly that activates three receptors: GLP-1, GIP and glucagon. The GLP-1 and GIP arms reduce appetite and improve insulin response. The glucagon arm is the new piece. It raises energy use in the liver and increases fat burning.
The results made it the most talked-about metabolic compound of the past two years. In the Phase 2 trial published in 2023, participants on the highest dose lost an average of 24.2% of body weight at 48 weeks (reference 1). In May 2026, Lilly reported that the Phase 3 TRIUMPH-1 trial produced an average 28.3% loss at the highest dose over 80 weeks (reference 2). It is not FDA approved as of September 2026. The full picture is in our retatrutide profile.
GHRH vs GHRP: two different doors to the same pituitary
Growth hormone is released in pulses, mostly in the first hours of deep sleep. Two hypothalamic signals control it: GHRH turns the pulse up and somatostatin turns it down. Ghrelin adds a separate “go” signal through its own receptor. That’s why there are two families of GH-releasing peptides:
- GHRH analogs (sermorelin, CJC-1295, tesamorelin) act on the GHRH receptor and amplify the natural pulse. A 2006 study showed CJC-1295 produced prolonged increases in GH and IGF-1 in healthy adults (reference 4). Tesamorelin is FDA approved for reducing excess abdominal fat in people with HIV-associated lipodystrophy, based on Phase 3 data (reference 5).
- GHRPs, or ghrelin-receptor agonists (ipamorelin and the older GHRPs) act on the GHS-R1a receptor. Ipamorelin was described in 1998 as the first selective GH secretagogue: in animal studies it raised GH without the cortisol and ACTH increases seen with earlier GHRPs (reference 3).
Because they use different receptors, one of each can complement the other. That is the reasoning behind the familiar CJC-1295 plus ipamorelin pairing.
The stacking rule people break: redundancy
Section 6.4 of the book calls receptor redundancy the most common stacking error in metabolic protocols, and one that’s easy to miss because the compounds have different names:
- Two GLP-1 agonists (for example retatrutide with semaglutide) hit the same receptor. The result is saturation and more side effects, not more benefit.
- Two GHRH analogs (for example CJC-1295 with tesamorelin) compete for the same pituitary receptor. The book’s rule is one GHRH analog, optionally paired with one ghrelin-receptor agonist.
Sequence: correct the metabolic signal first
Here’s where retatrutide and the GH peptides meet. Growth hormone raises blood sugar in the short term and reduces insulin sensitivity, a well-documented effect (reference 6). Visceral fat and high insulin also blunt the body’s GH response.
So Metabolic Precision (pp. 223–225) sets the order: correct metabolic signalling first, usually with an incretin-class compound, then add GH-axis support once glucose markers have improved. Adding GH peptides into an insulin-resistant, inflamed state can make the primary problem worse and produce a weaker GH response. The book also notes that correcting metabolic signalling often improves other hormones on its own, so some people never need the second layer.
Questions people ask
What is the difference between GHRH and GHRP?
GHRH analogs (such as CJC-1295, sermorelin and tesamorelin) work through the GHRH receptor and amplify natural GH pulses. GHRPs (such as ipamorelin) work through the ghrelin receptor. Because the receptors differ, one of each can complement the other, while two GHRH analogs together compete for the same receptor.
Can you take ipamorelin with retatrutide?
No clinical trial has studied that combination. The framework in Metabolic Precision (pp. 223–227) cautions against adding GH-axis peptides before blood sugar has stabilised, because growth hormone can reduce insulin sensitivity. Neither compound is FDA approved, and any combination should be discussed with a qualified clinician.
Is retatrutide better than tirzepatide?
Retatrutide adds a glucagon receptor arm to the GLP-1 and GIP activity tirzepatide already has, and its trial weight loss has been larger. The trials weren’t head to head, and retatrutide is still investigational. See our retatrutide profile for the comparison.
Why take CJC-1295 and ipamorelin together?
They act on two different receptors that both trigger GH release, so the pairing gives complementary stimulation. That’s the mechanism-level reasoning. Evidence for the combination in people is limited.
Where this comes from in our books
This article is the plain-language version. The book sections below go further, with full mechanism detail, evidence tiers and how each idea fits a complete protocol. Page numbers refer to the print editions.
Metabolic Precision
Sections 1.1 and 1.2, How Peptides Work; Why Peptides Are Central to Metabolic Biology · pp. 28–32
Metabolic Precision
Sections 6.2 and 6.4, integration and receptor redundancy · pp. 223–225, 240–241
Read next
Put the framework to work
The free Protocol Builder applies the same category-first logic as the books, built from the same compound database.
Open the Protocol BuilderSee the book seriesReferences
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526. View sourceCited in Metabolic Precision (p. 353)
- Eli Lilly and Company. Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. May 21, 2026. View source
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561. View sourceCited in Metabolic Precision (p. 354)
- Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805. View sourceCited in Metabolic Precision (p. 354)
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359–2370. View sourceCited in Metabolic Precision (p. 354)
- Møller N, Jørgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009;30(2):152–177. View source
How this article is maintained. Research and regulatory status change. We review our articles against current sources and update them as new information becomes available; the date at the top shows the last review.
Educational information only, not medical advice. Nothing in this article is a recommendation to use any compound or a dosing guide. Talk to a qualified clinician before starting, stopping or combining any compound.